Waldenström Macroglobulinemia: Review of Pathogenesis and Management

Seongseok Yun, Ariel C. Johnson, Onyemaechi N. Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz, Faiz Anwer

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.

Original languageEnglish (US)
Pages (from-to)252-262
Number of pages11
JournalClinical Lymphoma, Myeloma and Leukemia
Volume17
Issue number5
DOIs
StatePublished - May 2017

Keywords

  • CXCR4
  • Lymphoid neoplasm
  • Lymphoplasmacytic lymphoma
  • MYD88
  • Monoclonal immunoglobulin M

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Waldenström Macroglobulinemia: Review of Pathogenesis and Management'. Together they form a unique fingerprint.

  • Cite this

    Yun, S., Johnson, A. C., Okolo, O. N., Arnold, S. J., McBride, A., Zhang, L., Baz, R. C., & Anwer, F. (2017). Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clinical Lymphoma, Myeloma and Leukemia, 17(5), 252-262. https://doi.org/10.1016/j.clml.2017.02.028